Quarterly Financial Results and Product Approval - Research Reports on Pacira, PAREXEL, WellPoint, Illumina and St. Jude Medical

NEW YORK, November 4, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), PAREXEL International Corporation (NASDAQ: PRXL), WellPoint Inc. (NYSE: WLP), Illumina, Inc. (NASDAQ: ILMN) and St. Jude Medical, Inc. (NYSE: STJ). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7670-100free.

--
Pacira Pharmaceuticals Inc. Research Reports
On October 30, 2014, Pacira Pharmaceuticals Inc. (Pacira) reported its Q3 2014 and 9M 2014 earnings. The Company trimmed its Q3 2014 net loss to $3.0 million, from a net loss of $14.8 million in Q3 2013. Q3 2014 total revenues improved by a staggering 123.8% YoY to $52.0 million, led by 127.2% YoY improvement in its net product sales to $50.9 million. During the quarter, EXPAREL net product sales improved 151.0% YoY to $50.2 million. The Company's 9M 2014 total revenues improved 161.4% YoY to $135.9 million, while net loss stood at $19.5 million as compared to net loss of $52.0 million in 9M 2013. The full research reports on Pacira are available to download free of charge at:

http://www.analystsreview.com/Nov-04-2014/PCRX/report.pdf

--
PAREXEL International Corporation Research Reports
On October 29, 2014, PAREXEL International Corporation (PAREXEL) reported 8.4% YoY improvement in its Q1 FY 2015 (period ended September 30, 2014) total revenue to $573.7 million, reflecting 9.4% YoY growth in service revenue to $491.7 million. During the quarter, the Company's income from operations improved 27.9% to $53.6 million. The Company's Q3 2014 net income came in at $37.1 million or $0.67 per diluted share, compared to net income of $26.0 million or $0.45 per diluted share in Q3 2013. For Q2 FY 2015, the Company expects revenue in the range of $495 million - $508 million and GAAP EPS in the range of $0.56 - $0.62. For full-year FY 2015, the Company expects revenue in the range $2.070 - $2.110 billion and GAAP EPS in the range of $2.58 - $2.77. The full research reports on PAREXEL are available to download free of charge at:

http://www.analystsreview.com/Nov-04-2014/PRXL/report.pdf

--
WellPoint Inc. Research Reports
On October 29, 2014, WellPoint Inc. (WellPoint) posted 4.3% YoY growth in its Q3 2014 total operating revenues to $18.4 billion, reflecting increase in premium to cover overall cost trends and new fees associated with Health Care Reform, as well as higher enrollment in the Medicaid, Individual and Commercial self-funded businesses. The Company's Q3 2014 net income stood at $630.9 million or $2.22 per diluted share, compared to net income of $656.2 million or $2.16 per diluted share in Q3 2013. The Company's Q3 2014 adjusted net EPS stood at $2.36. On average, 22 analysts polled by Thomson Reuters expected Q3 2014 EPS (excluding special items) of $2.27 on revenue of $18.72 billion. The Company reported 9M 2014 total operating revenues of $54.2 billion, up 3.2% YoY and net income of $2.1 billion, down 11.9% YoY. For full-year 2014, the Company expects operating revenue in the range of $73.25 - $73.5 billion and net income per share between $8.83 and $8.93. The full research reports on WellPoint are available to download free of charge at:

http://www.analystsreview.com/Nov-04-2014/WLP/report.pdf

--
Illumina, Inc. Research Reports
On October 20, 2014, Illumina, Inc. (Illumina) reported its Q3 FY 2014 and 9M FY 2014 earnings (period ended September 28, 2014). The Company's Q3 FY 2014 total revenues soared 34.7% YoY to $480.6 million and income from operations improved by a staggering 162.8% YoY to $119.5 million. During the quarter, the Company's product revenue improved 30.6% YoY to $416.2 million, while service and other revenue improved 68.8% YoY to $64.5 million. The Company's Q3 FY 2014 net income almost tripled to $93.5 million from $31.4 million in Q3 FY 2013. The Company's Q3 FY 2014 adjusted diluted EPS came in at $0.77, ahead of $0.44 per share predicted by 20 analysts polled by Thomson Reuters on an average. Analysts polled by Thomson Reuters expected the Company to report revenue of $451.2 million for the quarter. The Company's 9M FY 2014 total revenue improved 30.5% YoY to $1.3 billion, while net income came in at $200.1 million, up 348.1% YoY. The full research reports on Illumina are available to download free of charge at:

http://www.analystsreview.com/Nov-04-2014/ILMN/report.pdf

--
St. Jude Medical, Inc. Research Reports
On October 27, 2014, St. Jude Medical, Inc. (St. Jude Medical) announced that the U.S. Food and Drug Administration (FDA) approval of its TactiCath™ Quartz irrigated ablation catheter - its newest technology that provides physicians a real-time, objective measure of the force that the catheter applies to a patient's heart wall during an ablation procedure. The Company informed that TactiCath Quartz contact-force technology was designed to provide physicians with more control to modify that force during ablation procedures in order to create more effective lesions for patients being treated for paroxysmal atrial fibrillation (AF). Further, the TactiCath Quartz ablation catheter provides electrophysiologists the ability to monitor the amount of pressure that a catheter tip exerts on the endocardium (the layer of tissue that lines the chambers of the heart). The full research reports on St. Jude Medical are available to download free of charge at:

http://www.analystsreview.com/Nov-04-2014/STJ/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED